MétaCan
Menu
Back to cohort
Record W4394936275 · doi:10.1055/s-0044-1785403

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)

2024· article· en· W4394936275 on OpenAlexaff
Louis J. Aronne, Naveed Sattar, Deborah B. Horn, Harold Bays, Sean Wharton, Wen‐Yuan Lin, Nadia Nazir Ahmad, Shuyu Zhang, Ran Liao, Mathijs C. Bunck, Irina Jouravskaya, Madhumita A. Murphy, Thomas Ebert

Bibliographic record

VenueDiabetologie und Stoffwechsel · 2024
Typearticle
Languageen
FieldMedicine
TopicPharmacology and Obesity Treatment
Canadian institutionsMcMaster University
Fundersnot available
KeywordsOverweightWeight lossObesityMedicineReduction (mathematics)Affect (linguistics)PediatricsInternal medicinePsychologyMathematics

Abstract

fetched live from OpenAlex

How does once-weekly subcutaneous tirzepatide affect maintenance of weight loss in individuals with obesity or overweight? Methods : SURMOUNT-4 is a phase 3, double-blind, 88-week study that investigates the maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg QW), compared with placebo, on the maintenance of weight loss for 52 weeks after an initial 36-week open-label tirzepatide lead-in treatment period. In the study, participants without T2DM and with obesity (BMI ≥30 kg/m^2) or overweight (BMI ≥27 kg/m^2) with at least 1 weight-related comorbid condition were enrolled. The efficacy estimand was used to assess efficacy which represented the average treatment effect, prior to treatment discontinuation. Results : 803 participants enrolled in the lead-in period and 670 were randomized to continue tirzepatide MTD (N=335) or switch to placebo (N=335). For randomized participants, the mean weight loss was 20.9% following 36-week open-label treatment. SURMOUNT-4 met the primary endpoint. From week 36 to week 88, those taking tirzepatide had an additional weight change of -6.7%, while those taking placebo had a mean weight regain of 14.8%. The percentage of participants at 88 weeks who maintained ≥80% of the weight loss during the lead-in period was 93.4% with tirzepatide and 13.5% with placebo. In addition, participants who remained on tirzepatide achieved a total of 26.0% mean weight loss over the 88-week period. The most frequent adverse events with tirzepatide were gastrointestinal disorders, generally being mild to moderate in severity. Conclusion : In this 88-week trial in participants with obesity or overweight, withdrawing tirzepatide after 36 weeks treatment led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction. ^ denotes square root in this submission Publication History Article published online: 18 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.296
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueDiabetologie und StoffwechselSame topicPharmacology and Obesity TreatmentFrench-language works237,207